CEO of Mylan---I am hearing on CNBC that the salary of the CEO is also outrageous & a topic of conversation plus they (Mylan) did a tax inversion last year. The optics as they say do not look good.
---also congress who control the FDA is part of the problem... re: approval time for competitors'drugs is too long & patent expiry too long which prevents competition.
---US drug/medicine costs are not subjective to price controls that every other country has who limit/adjust monopolies & prices allowed to be charged to consumers accordingly.
---US research costs are recovered thru prices hikes bottom line.
carlos